Tim-3 identifies exhausted follicular helper T cells in breast cancer patients

Immunobiology

Volumn 221, Issue 9, 2016, Pages 986-993

  Zhu, Shiguang ^a   Lin, Jun ^a   Qiao, Guangdong ^a   Wang, Xingmiao ^a   Xu, Yanping ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Breast cancer; Tfh; Tim 3

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CXCL13 CHEMOKINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 21; LYMPHOCYTE SURFACE MARKER; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TIM 3; UNCLASSIFIED DRUG; CXCL13 PROTEIN, HUMAN; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN DERIVATIVE;

ADULT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FOLLICULAR HELPER T CELL; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS INFECTION; BREAST TUMOR; IMMUNOLOGY; MIDDLE AGED;

BREAST NEOPLASMS; CHEMOKINE CXCL13; FEMALE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKINS; MIDDLE AGED; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84964900058     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2016.04.005     Document Type: Article

References (45)

1. Anderson A.C. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2014, 2:393-398. 10.1158/2326-6066.CIR-14-0039.
2. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
3. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.R., Freeman G.J., Vignali D.A.A., Wherry E.J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37. 10.1038/ni.1679.
4. Coleman M.P., Quaresma M., Berrino F., Lutz J.M., De Angelis R., Capocaccia R., Baili P., Rachet B., Gatta G., Hakulinen T., Micheli A., Sant M., Weir H.K., Elwood J.M., Tsukuma H., Koifman S., Silva G.A., Francisci S., Santaquilani M., Verdecchia A., Storm H.H., Young J.L. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008, 9:730-756. 10.1016/S1470-2045(08)70179-7.
5. Crotty S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 2011, 29:621-663. 10.1146/annurev-immunol-031210-101400.
6. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M., Wherry E.J., Coovadia H.M., Goulder P.J.R., Klenerman P., Ahmed R., Freeman G.J., Walker B.D. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
7. Desantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. Cancer 2011, 61:409-418. 10.3322/caac.20134.Available.
8. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363:1938-1948. 10.1056/NEJMra1001389.
9. Franceschini D., Paroli M., Francavilla V., Videtta M., Morrone S., Labbadia G., Cerino A., Mondelli M.U., Barnaba V. PD-L1 negatively regulates CD4 + CD25 + Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 2009, 119:551-564. 10.1172/JCI36604.
10. Francisco L.M., Sage P.T., Sharpe A.H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 2010, 10.1111/j.1600-065x.2010.00923.x.
11. Fuss I.J., Kanof M.E., Smith P.D., Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr. Protoc. Immunol. 2009, 1-8. 10.1002/0471142735.im0701s85.
12. Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., Arfl V., Biota C., Doffin A.C., Durand I., Olive D., Perez S., Pasqual N., Faure C., Ray-Coquard I., Puisieux A., Caux C., Blay J.Y., Ménétrier-Caux C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical utcome. Cancer Res. 2009, 69:2000-2009. 10.1158/0008-5472.CAN-08-2360.
13. Golden-Mason L., Palmer B.E., Kassam N., Townshend-Bulson L., Livingston S., McMahon B.J., Castelblanco N., Kuchroo V., Gretch D.R., Rosen H.R. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J. Virol. 2009, 83:9122-9130. 10.1128/JVI.00639-09.
14. Good-Jacobson K.L., Szumilas C.G., Chen L., Sharpe A.H., Tomayko M.M., Shlomchik M.J. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat. Immunol. 2010, 11:535-542. 10.1038/ni.1877.
15. Gu-Trantien C., Loi S., Garaud S., Equeter C., Libin M., Wind A., Ravoet De, Buanec M., Le H., Sibille C., Manfouo-Foutsop G., Veys I., Haibe-Kains B., Singhal S.K., Michiels S., Rothé F., Salgado R., Duvillier H., Ignatiadis M., Desmedt C., Bron D., Larsimont D., Piccart M., Sotiriou C., Willard-Gallo K. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest 2013, 123:1-20. 10.1172/JCI67428.
16. Hastings W.D., Anderson D.E., Kassam N., Koguchi K., Greenfield E.A., Kent S.C., Xin X.Z., Strom T.B., Hafler D.A., Kuchroo V.K. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur. J. Immunol. 2009, 39:2492-2501. 10.1002/eji.200939274.
17. Haynes N.M., Allen C.D.C., Lesley R., Ansel K.M., Killeen N., Cyster J.G. Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J. Immunol. 2007, 179:5099-5108. 10.4049/jimmunol.179.8.5099.
18. Igene H. Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J. 2002, 14:428-434. 10.1111/j.1524-4741.2008.00618.x.
19. Jones R.B., Ndhlovu L.C., Barbour J.D., Sheth P.M., Jha A.R., Long B.R., Wong J.C., Satkunarajah M., Schweneker M., Chapman J.M., Gyenes G., Vali B., Hyrcza M.D., Yue F.Y., Kovacs C., Sassi A., Loutfy M., Halpenny R., Persad D., Spotts G., Hecht F.M., Chun T.-W., McCune J.M., Kaul R., Rini J.M., Nixon D.F., Ostrowski M.A. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 2008, 205:2763-2779. 10.1084/jem.20081398.
20. Kawamoto S., Tran T.H., Maruya M., Suzuki K., Doi Y., Tsutsui Y., Kato L.M., Fagarasan S. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science 2012, 336(6080):485-489. 10.1126/science.1217718.
21. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704. 10.1146/annurev.immunol.26.021607.090331.
22. Locci M., Havenar-Daughton C., Landais E., Wu J., Kroenke M.A., Arlehamn C.L., Su L.F., Cubas R., Davis M.M., Sette A., Haddad E.K., Poignard P., Crotty S. Human circulating PD-1 + CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013, 39:758-769. 10.1016/j.immuni.2013.08.031.
23. Lussier D.M., O'Neill L., Nieves L.M., McAfee M.S., Holechek S.A., Collins A.W., Dickman P., Jacobsen J., Hingorani P., Blattman J.N. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J. Immunother. 2015, 38:96-106. 10.1097/CJI.0000000000000065.
24. Mahmoud S.M.A., Lee A.H.S., Paish E.C., MacMillan R.D., Ellis I.O., Green A.R. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res. Treat. 2012, 132:545-553. 10.1007/s10549-011-1620-1.
25. McDermott D.F., Atkins M.B. PD-1 as a potential target in cancer therapy. Cancer Med. 2013, 2:662-673. 10.1002/cam4.106.
26. McHeyzer-Williams M., Okitsu S., Wang N., McHeyzer-Williams L. Molecular programming of B cell memory. Nat. Rev. Immunol. 2012, 12:24-34. 10.1038/nri3128.
27. McMahan R.H., Golden-Mason L., Nishimura M.I., McMahon B.J., Kemper M., Allen T.M., Gretch D.R., Rosen H.R. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 2010, 120:4546-4557. 10.1172/JCI43127.
28. Miller E., Lee H.J., Lulla A., Hernandez L., Gokare P., Lim B. Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. F1000Research 2014, 3:198. 10.12688/f1000research.4340.1.
29. Monney L., Sabatos C.A., Gaglia J.L., Ryu A., Waldner H., Chernova T., Manning S., Greenfield E.A., Coyle A.J., Sobel R.A., Freeman G.J., Kuchroo V.K. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541. 10.1038/415536a.
30. Morita R., Schmitt N., Bentebibel S., Ranganathan R., Bourdery L., Zurawski G., Foucat E., Dullaers M., Oh S., Sabzghabaei N., Lavecchio E.M., Punaro M., Pascual V. Follicular cells and contain specific subsets that differentially. Immunity 2011, 28:108-121. 10.1016/j.immuni.2010.12.012.Human.
31. Morita R., Schmitt N., Bentebibel S.E., Ranganathan R., Bourdery L., Zurawski G., Foucat E., Dullaers M., Oh S., Sabzghabaei N., Lavecchio E.M., Punaro M., Pascual V., Banchereau J., Ueno H. Human blood CXCR5 + CD4+ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011, 34:108-121. 10.1016/j.immuni.2010.12.012.
32. Morrow M., Waters J., Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet 2011, 378:1804-1811. 10.1016/S0140-6736(11)61350-0.
33. Mujib S., Jones R.B., Lo C., Aidarus N., Clayton K., Sakhdari A., Benko E., Kovacs C., Ostrowski M. Antigen-independent induction of Tim-3 expression on human T cells by the common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J. Immunol. 2012, 188:3745-3756. 10.4049/jimmunol.1102609.
34. Nelson B.H. CD20+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 2010, 185:4977-4982. 10.4049/jimmunol.1001323.
35. Ngiow S.F., Von Scheidt B., Akiba H., Yagita H., Teng M.W.L., Smyth M.J. Anti-TIM3 antibody promotes T cell IFN-??-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011, 71:3540-3551. 10.1158/0008-5472.CAN-11-0096.
36. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., Precopio M.L., Schacker T., Roederer M., Douek D.C., Koup R.A. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 2006, 203:2281-2292.
37. Reeler V., Sikora K., Solomon B. Overcoming challenges of cancer treatment programmes in developing countries: a sustainable breast cancer initiative in Ethiopia. Clin. Oncol. (R. Coll. Radiol.) 2008, 20:191-198. 10.1016/j.clon.2007.11.012.
38. Ruffell B., DeNardo D.G., Affara N.I., Coussens L.M. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010, 21:3-10. 10.1016/j.cytogfr.2009.11.002.
39. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207:2187-2194. 10.1084/jem.20100643.
40. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., McMiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454. 10.1056/NEJMoa1200690.
41. Yang Z.-Z., Grote D.M., Ziesmer S.C., Niki T., Hirashima M., Novak A.J., Witzig T.E., Ansell S.M. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Invest. 2012, 122:1271-1282. 10.1172/JCI59806.
42. Zamarron B.F., Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci. 2011, 7:651-658. 10.7150/ijbs.7.651.
43. Zhou Q., Munger M.E., Veenstra R.G., Weigel B.J., Hirashima M., Munn D.H., Murphy W.J., Azuma M., Anderson A.C., Kuchroo V.K., Blazar B.R. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2015, 117:4501-4511. 10.1182/blood-2010-10-310425.The.
44. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B., Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6:1245-1252. 10.1038/ni1271.
45. Zhu C., Anderson A.C., Kuchroo V.K. TIM-3 and its regulatory role in immune responses. Curr. Top. Microbiol. Immunol. 2010, 350:1-15. 10.1007/82_2010_84.